

Joseph L Kuti

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4532858/joseph-l-kuti-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

3,525
citations

31
h-index

55
g-index

148
ext. papers

4,172
ext. citations

5.3
avg, IF

5.45
L-index

#	Paper	IF	Citations
140	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 498-509	25.5	534
139	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1725-30	5.9	208
138	Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 1116-23	2.9	143
137	Clinical pharmacodynamics of cefepime in patients infected with <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1111-6	5.9	89
136	Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1476-81	5.9	89
135	Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2464-70	5.9	89
134	Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. <i>Clinical Therapeutics</i> , 2004 , 26, 1187-98	3.5	85
133	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 388-95	5.1	81
132	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S47-S47	1	78
131	1398. Lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) Based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S430-S430	1	78
130	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011 , 37, 632-8	14.5	69
129	Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. <i>Drugs</i> , 2006 , 66, 1-14	12.1	68
128	Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. <i>Journal of Critical Care</i> , 2010 , 25, 69-77	4	65
127	Optimal dosing of piperacillin-tazobactam for the treatment of <i>Pseudomonas aeruginosa</i> infections: prolonged or continuous infusion?. <i>Pharmacotherapy</i> , 2007 , 27, 1490-7	5.8	63
126	Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 379-85	3	60
125	Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. <i>Clinical Therapeutics</i> , 2004 , 26, 493-501	3.5	60
124	Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1359-64	5.9	55

123	In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 202-7	5.9	54
122	In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 874-9	5.9	52
121	Prolonging β -lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 105-13	14.3	49
120	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant <i>Staphylococcus aureus</i> with a range of vancomycin MICs in a murine pneumonia model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5115-9	5.9	49
119	Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 168-73	3.4	47
118	Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 337-44	2.9	47
117	Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. <i>American Journal of Health-System Pharmacy</i> , 2002 , 59, 2209-15	2.2	45
116	Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 69-75	2.9	36
115	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1401-10	5.9	35
114	Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> using Monte Carlo analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002 , 44, 51-7	2.9	34
113	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 617-633	6.2	33
112	Continuous and Prolonged Intravenous β -Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016 , 29, 759-72	34	32
111	The Essential Role of Pharmacists in Antimicrobial Stewardship. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 753-4	2	32
110	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 83, 53-5	2.9	31
109	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6578-6584	5.9	31
108	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 342-3	14.3	31
107	Making the most of surveillance studies: summary of the OPTAMA Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 53, 281-7	2.9	30
106	Empiric treatment of multidrug-resistant <i>Burkholderia cepacia</i> lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. <i>Pharmacotherapy</i> , 2004 , 24, 1641-5	5.8	30

105	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003 , 60, 565-8	2.2	29
104	Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. <i>Pharmacotherapy</i> , 2013 , 33, 266-74	5.8	28
103	Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, <i>Acinetobacter baumannii</i> , and <i>Pseudomonas aeruginosa</i> . <i>Pharmacotherapy</i> , 2004 , 24, 8-15	5.8	28
102	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 452-7	14.3	25
101	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1546-1553	5.1	24
100	Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. <i>Pharmacotherapy</i> , 2010 , 30, 453-62	5.8	24
99	Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against <i>Pseudomonas aeruginosa</i> infections in children: a report from the OPTAMA program. <i>Clinical Therapeutics</i> , 2005 , 27, 1820-30	3.5	24
98	Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 62-8	14.3	23
97	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
96	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019 , 20, 55-61	2	22
95	Carbapenem-Nonsusceptible Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	21
94	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 459-76	3.8	21
93	Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. <i>Pharmacotherapy</i> , 2005 , 25, 935-41	5.8	21
92	Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clinical Infectious Diseases</i> , 2014 , 59, 905-7	11.6	20
91	Treatment of <i>Serratia marcescens</i> meningitis with prolonged infusion of meropenem. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1077-81	2.9	20
90	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 712-719	2.9	19
89	An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 78-83	2.2	19
88	Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. <i>Pharmacoeconomics</i> , 2002 , 20, 513-28	4.4	19

87	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 583-9	2	19
86	In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 672-7	5.9	18
85	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	17
84	Mortality, Hospital Costs, Payments, and Readmissions Associated With Infection Among Medicare Beneficiaries. <i>Infectious Diseases in Clinical Practice</i> , 2015 , 23, 318-323	0.2	17
83	Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 102-15	3.9	16
82	Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. <i>Pharmacoeconomics</i> , 2004 , 22, 301-10	4.4	16
81	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 189-95	5.1	15
80	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1240-1246	11.6	15
79	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 397-408	4	15
78	In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7520-6	5.9	15
77	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021 , 41, 220-233	5.8	15
76	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2064-7	5.1	14
75	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 215-8	2	14
74	Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
73	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a Goldilocks Window. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 487-490	14.3	13
72	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis [A review of 3 cases]. <i>Respiratory Medicine CME</i> , 2010 , 3, 146-149		12
71	Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007 , 29, 889-899	3.5	12
70	Defining the potency of amikacin against , and derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018 , 11, 783-790	4.2	11

69	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
68	Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. <i>Chemotherapy</i> , 2005 , 51, 211-6	3.2	11
67	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
66	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 294-297	2.9	10
65	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018 , 40, 261-269	3.5	10
64	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014 , 3, 269-79	6.2	10
63	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106299	14.3	10
62	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	9
61	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018 , 18, 932	2.9	9
60	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019 , 8, 383-396	6.2	8
59	Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 705-720	5.5	8
58	Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
57	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019 , 41, 1453-1462	3.5	7
56	Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2011 , 68, 2265-70	2.2	7
55	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, e36-e44	2.2	7
54	Effects of Clinically Meaningful Concentrations of Antipseudomonal β -Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3502-3512 ⁶	9.7	6
53	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 512-8	14.3	6
52	Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. <i>Surgical Infections</i> , 2008 , 9, 57-66	2	6

51	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1048-1056	2.2	6
50	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	5
49	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
48	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5
47	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 1480-4	2.2	5
46	Monte Carlo Simulation Methodologies for β -Lactam/ β -Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 172-180	2.9	5
45	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 955-61	5.9	5
44	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β -Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	4
43	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	4
42	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
41	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021 , 20, 9	6.2	4
40	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 247-8	14.3	3
39	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106395	14.3	3
38	Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Man.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 833189	5.6	3
37	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 698-702	14.3	2
36	Imipenem/Cilastatin/Relebactam Alone and in Combination against in the Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
35	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy206	1	2
34	Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. <i>Connecticut Medicine</i> , 2009 , 73, 337-40		2

33	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e55-e63	2.2	1
32	Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 482-494	5.4	1
31	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020 , 42, 606-613	3.5	1
30	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 222-8	5.9	1
29	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019 , 41, 2162-2170	3.5	1
28	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 593-599	1.3	1
27	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004 , 39, 1069-1075	1.1	1
26	Cefditoren Pivoxil. <i>Drugs</i> , 2002 , 62, 337-338	12.1	1
25	In vitro Time Kill of Trimethoprim/Sulfamethoxazole against versus using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0216721	5.9	1
24	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	1
23	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 256-9	0.5	1
22	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
21	888. <i>Critical Care Medicine</i> , 2019 , 47, 423	1.4	1
20	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019 , 69, 903-904	11.6	0
19	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S670-S670	1	0
18	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S635-S635	1	0
17	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106603	14.3	0
16	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019 , 2, 444-445	1.4	

- 15 Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. *Clinical Medicine Therapeutics*, **2009**, 1, CMT.S2062
- 14 Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. *Journal of Medical Microbiology*, **2008**, 57, 1147-1151 3.2
- 13 1103. Minocycline (MIN) Pharmacodynamics (PD) against *Stenotrophomonas maltophilia* (STM) in a Neutropenic Murine Thigh Infection Model. *Open Forum Infectious Diseases*, **2021**, 8, S643-S643 1
- 12 Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. *Hospital Pharmacy*, 001857872110557 1.1
- 11 1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. *Open Forum Infectious Diseases*, **2020**, 7, S667-S667 1
- 10 13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against *Pseudomonas Aeruginosa* (psa) from Patients with Cystic Fibrosis (CF). *Open Forum Infectious Diseases*, **2020**, 7, S7-S8 1
- 9 1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against *Pseudomonas aeruginosa* (PSA) from Patients with Cystic Fibrosis (CF). *Open Forum Infectious Diseases*, **2020**, 7, S797-S797 1
- 8 112. Impact of Respiratory Viral PCR Panels (RVP) and Serum Procalcitonin (PCT) on Antibiotic Days of Therapy (DOT) in Patients Admitted with Lower Respiratory Tract Infections (LRTI). *Open Forum Infectious Diseases*, **2020**, 7, S70-S70 1
- 7 1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against *Pseudomonas aeruginosa* (PSA) in the In Vitro Pharmacodynamic Model. *Open Forum Infectious Diseases*, **2020**, 7, S667-S667 1
- 6 CMO OPTIMIZAR LA FARMACODINAMIA ANTIMICROBIANA: UNA GUÍA PARA UN PROGRAMA DE OPTIMIZACIÓN DEL USO DE ANTIMICROBIANOS. *Revista Médica Clínica Las Condes*, **2016**, 27, 625-635 0.2
- 5 Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. *Connecticut Medicine*, **2003**, 67, 85-8
- 4 1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). *Open Forum Infectious Diseases*, **2021**, 8, S646-S646 1
- 3 58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. *Open Forum Infectious Diseases*, **2021**, 8, S147-S148 1
- 2 65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against *Stenotrophomonas maltophilia* (STM). *Open Forum Infectious Diseases*, **2021**, 8, S44-S44 1
- 1 A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?. *Journal of Pharmacy Practice*, **2021**, 8971900211063301 1.3